
LENSAR LNSR
$ 6.09
0.5%
Annual report 2025
added 03-31-2026
LENSAR Book Value 2011-2026 | LNSR
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value LENSAR
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.2 M | 18.6 M | 47.2 M | 42 M | 54.9 M | 67.2 M | -30.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67.2 M | -30.6 M | 26.7 M |
Quarterly Book Value LENSAR
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.1 M | -9.27 M | -8.36 M | 18.6 M | 36.5 M | 37.4 M | - | 47.2 M | 50.1 M | 46.4 M | 39.4 M | 42 M | 42.6 M | 44.9 M | 49.8 M | 54.9 M | 57 M | 61.6 M | 64.3 M | 67.2 M | 67.2 M | 67.2 M | 67.2 M | -30.6 M | -30.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 67.2 M | -30.6 M | 36.3 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abbott Laboratories
ABT
|
86.7 B | $ 102.18 | -0.67 % | $ 178 B | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 11.98 | -0.42 % | $ 1.62 B | ||
|
Align Technology
ALGN
|
3.85 B | $ 170.34 | -0.15 % | $ 12.8 B | ||
|
Apyx Medical Corporation
APYX
|
14.8 M | $ 3.68 | -0.14 % | $ 151 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 10.86 | 0.28 % | $ 1.63 B | ||
|
AxoGen
AXGN
|
129 M | $ 33.95 | -1.44 % | $ 1.56 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.13 | 0.49 % | $ 874 M | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 36.83 | 0.19 % | $ 5.49 K | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 62.71 | -0.18 % | $ 92.8 B | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 9.42 | 0.53 % | $ 267 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 34.68 | -0.32 % | $ 1.08 B | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.6 | 2.92 % | $ 37.3 M | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.75 | 1.25 % | $ 349 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
EDAP TMS S.A.
EDAP
|
56.9 M | $ 3.38 | -0.44 % | $ 127 M | ||
|
Electromed
ELMD
|
43.2 M | $ 23.29 | - | $ 197 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 80.81 | -0.3 % | $ 47.3 B | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.58 | -0.05 % | $ 122 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Globus Medical
GMED
|
4.57 B | $ 87.99 | 0.08 % | $ 11.9 B | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.96 | 5.52 % | $ 1.19 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 9.46 | -0.73 % | $ 729 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Inogen
INGN
|
192 M | $ 6.24 | 0.48 % | $ 166 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 56.41 | 2.58 % | $ 1.66 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.0 | 2.52 % | $ 16.9 M | ||
|
IRadimed Corporation
IRMD
|
94.6 M | $ 95.03 | -1.25 % | $ 1.21 B | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 85.96 | -1.02 % | $ 2.99 B | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 16.06 | - | $ 377 M |